Is Abbott Laboratories (ABT) overvalued? · P/E 25, rev $44.33B
Abbott Laboratories (ABT) is a medical devices company listed on NYSE.
This page asks whether Abbott Laboratories (ABT) looks expensive on cached numbers — not a short thesis.
Latest reported ABT revenue for 2025-12-31 was $44.33B. Net income was $6.52B. Revenue was up 5.7% from 2024-12-31 to 2025-12-31. ABT currently screens at market cap $154.15B and trailing P/E 24.8.
ABT currently screens at market cap $154.15B and trailing P/E 24.8. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next ABT 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the ABT stock page for the full model, not this heading.
Not investment advice.